

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : B65D 83/14, A61K 9/00, A61M 15/00, B05D 5/08</p>		<p>A1</p>	<p>(11) International Publication Number: WO 96/32345 (43) International Publication Date: 17 October 1996 (17.10.96)</p>
<p>(21) International Application Number: PCT/US96/05009</p>		<p>Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US).</p>	
<p>(22) International Filing Date: 11 April 1996 (11.04.96)</p>		<p>(74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US) et al.</p>	
<p>(30) Priority Data: 08/422,280 14 April 1995 (14.04.95) US</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
<p>(60) Parent Application or Grant (63) Related by Continuation US 08/422,280 (CIP) Filed on 14 April 1995 (14.04.95)</p>		<p>Published <i>With international search report.</i></p>	
<p>(71) Applicant (<i>for all designated States except US</i>): GLAXO WELLCOME INC. [US/US]; 5 Moore Drive, Research Triangle Park, NC 27709 (US).</p>			
<p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): ASHURST, Ian, C. [GB/GB]; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US). HERMAN, Craig, S. [US/US]; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US). LI, Li [CH/US]; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US). RIEBE, Michael, T. [US/US]; Glaxo</p>			
<p>(54) Title: METERED DOSE INHALER FOR BECLOMETHASONE DIPROPIONATE</p>			
<p>(57) Abstract</p>			
<p>A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**METERED DOSE INHALER FOR
BECLOMETHASONE DIPROPIONATE****BACKGROUND OF THE INVENTION**

5

Drugs for treating respiratory and nasal disorders are frequently administered in aerosol formulations through the mouth or nose. One widely used method for dispensing such aerosol drug formulations involves making a suspension formulation of the drug as a finely divided powder in a liquefied gas known as a propellant. The suspension is stored in a sealed container capable of 10 withstanding the pressure required to maintain the propellant as a liquid. The suspension is dispersed by activation of a dose metering valve affixed to the container.

15

A metering valve may be designed to consistently release a fixed, predetermined mass of the drug formulation upon each activation. As the suspension is forced from the container through the dose metering valve by the high vapor pressure of the propellant, the propellant rapidly vaporizes leaving a fast moving cloud of very fine particles of the drug formulation. This cloud of 20 particles is directed into the nose or mouth of the patient by a channelling device such as a cylinder or open ended cone. Concurrently with the activation of the aerosol dose metering valve, the patient inhales the drug particles into the lungs or nasal cavity. Systems of dispensing drugs in this way are known as "metered dose inhalers" (MDI's). See Peter Byron, *Respiratory Drug Delivery*, 25 CRC Press, Boca Raton, FL (1990) for a general background on this form of therapy.

30

Patients often rely on medication delivered by MDI's for rapid treatment of respiratory disorders which are debilitating and in some cases, even life threatening. Therefore, it is essential that the prescribed dose of aerosol medication delivered to the patient consistently meet the specifications claimed by the manufacturer and comply with the requirements of the FDA and other

regulatory authorities. That is, every dose in the can must be the same within close tolerances.

Some aerosol drugs tend to adhere to the inner surfaces, i.e., walls of the can, valves, and caps, of the MDI. This can lead to the patient getting significantly less than the prescribed amount of drug upon each activation of the MDI. The problem is particularly acute with hydrofluoroalkane (also known as simply "fluorocarbon" propellant systems, e.g., P134a and P227, under development in recent years to replace chlorofluorocarbons such as P11, P114, and P12.

We have found that coating the interior can surfaces of MDI's with a fluorocarbon polymer significantly reduces or essentially eliminates the problem of drug adhesion or deposition on the can walls and thus ensures consistent delivery of medication in aerosol form from the MDI.

15

SUMMARY OF THE INVENTION

A metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

25

DETAILED DESCRIPTION OF THE INVENTION

The term "metered dose inhaler" or "MDI" means a unit comprising a can, a crimped cap covering the mouth of the can, and a drug metering valve situated in the cap, while the term "MDI system" also includes a suitable channelling device. The terms "MDI can" means the container without the cap and valve. The term "drug metering valve" or "MDI valve" refers to a valve and its associated mechanisms which delivers a predetermined amount of drug formulation from an MDI upon each activation. The channelling device may

comprise, for example, an actuating device for the valve and a cylindrical or cone-like passage through which medicament may be delivered from the filled MDI can via the MDI valve to the nose or mouth of a patient, e.g. a mouthpiece actuator. The relation of the parts of a typical MDI is illustrated in US Patent

5 5,261,538 incorporated herein by reference.

U.S. Patent No.3,312,590, incorporated herein by reference, teaches an antiinflammatory steroid compound know by the chemical name 9-chloro-1 1D, 17, 21-trihydroxy-16fi-methylprergna-1,4-diene-3, 20-dione 17, 21-dipropionate and the generic name "beclomethasone dipropionate". Beclomethasone dipropionate in aerosol form, has been accepted by the medical community as useful in the treatment of asthma and is marketed under the trademarks "Beclovent", "Becotide", and "Beconase".

15 The term "drug formulation" means beclomethasone dipropionate (or a physiologically acceptable solvate thereof) optionally in combination with one or more other pharmacologically active agents such as other antiinflammatory agents, analgesic agents or other respiratory drugs and optionally containing one or more excipients. The term "excipients" as used herein mean chemical 20 agents having little or no pharmacological activity (for the quantities used) but which enhance the drug formulation or the performance of the MDI system. For example, excipients include but are not limited to surfactants, preservatives, flavorings, antioxidants, antiaggregating agents, and cosolvents, e.g., ethanol and diethyl ether.

25 Suitable surfactants are generally known in the art, for example, those surfactants disclosed in European Patent Application No. 0327777. The amount of surfactant employed is desirable in the range of 0.0001% to 50% weight to weight ratio relative to the drug, in particular, 0.05 to 5% weight to weight ratio. A particularly useful- surfactant is 1,2-di[7-(F-hexyl) hexanoyl]-glycero-3-phospho-30 N,N,N-trimethylethanolamine also know as 3, 5, 9-trioxa-4-phosphadocosan-1-aminium, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 22, 22, 22-tridecafluoro-7-[(8, 8, 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 13-tridecafluoro-1-oxotridecyl)oxy]-4-hydroxy-N, N, N-trimethyl-10-oxo-, inner salt.,4-oxide.

A polar cosolvent such as C_{2-6} aliphatic alcohols and polyols eg ethanol, isopropanol and propylene glycol, and preferably ethanol, may be included in the drug formulation in the desired amount, either as the only excipient or in addition

5 to other excipients such as surfactants. Suitably, the drug formulation may contain 0.01 to 5% w/w based on the propellant of a polar cosolvent eg ethanol, preferably 0.1 to 5% w/w e.g. 0.1 to 1% w/w.

It will be appreciated by those skilled in the art that the drug formulation for use in

10 the invention may, if desired, contain beclomethasone dipropionate (or a physiologically acceptable solvate thereof) in combination with one or more other pharmacologically active agents. Such medicaments may be selected from any suitable drug useful in inhalation therapy. Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine,

15 ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; antiinfectives e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. fluticasone (e.g. the propionate), flunisolide, budesonide, tipredane or

20 triamcinolone acetonide; antitussives, e.g. noscapine; bronchodilators, e.g. salbutamol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline, or (-)-4-amino-3,5-dichloro-

α -{[(6-[2-(2-pyridinyl)ethoxy]hexyl)amino]methyl}benzenemethanol;

25 diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and

therapeutic proteins and peptides, e.g. insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as

30 esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

Particularly preferred drug formulations contain beclomethasone dipropionate (or a physiologically acceptable solvate thereof) in combination with a bronchodilator such as salbutamol (e.g. as the free base or the sulphate salt) or salmeterol (e.g. as the xinafoate salt).

5

"Propellants" used herein mean pharmacologically inert liquids with boiling points from about room temperature (25°C) to about -25°C which singly or in combination exert a high vapor pressure at room temperature. Upon activation of the MDI system, the high vapor pressure of the propellant in the MDI forces a metered amount of drug formulation out through the metering valve then the propellant very rapidly vaporizes dispersing the drug particles. The propellants used in the present invention are low boiling fluorocarbons; in particular, 1,1,1,2-tetrafluoroethane also known as "propellant 134a" or "P134a" and 1,1,1,2,3,3,3-heptafluoropropane also known as "propellant 227" or "P 227".

10

Drug formulations for use in the invention may be free or substantially free of formulation excipients e.g. surfactants and cosolvents etc. Such drug formulations are advantageous since they may be substantially taste and odour free, less irritant and less toxic than excipient-containing formulations. Thus, a preferred drug formulation consists essentially of beclomethasone dipropionate (or a physiologically acceptable solvate thereof), optionally in combination with one or more other pharmacologically active agents particularly salbutamol (or a physiologically acceptable salt thereof), and a fluorocarbon propellant. Preferred propellants are 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane.

15

Most often the MDI can and cap are made of aluminum or an alloy of aluminum, although other metals not affected by the drug formulation, such as stainless steel, an alloy of copper, or tin plate, may be used. An MDI can may also be fabricated from glass or plastic. Preferably, however, the MDI cans employed in the present invention are made of aluminium or an alloy thereof. Advantageously, strengthened aluminium or aluminum alloy MDI cans may be employed. Such strengthened MDI cans are capable of withstanding particularly stressful coating and curing conditions, e.g. particularly high temperatures, which

20

25

30

may be required for certain fluorocarbon polymers. Strengthened MDI cans which have a reduced tendency to malform under high temperatures include MDI cans comprising side walls and a base of increased thickness and MDI cans comprising a substantially ellipsoidal base (which increases the angle between the side walls and the base of the can), rather than the hemispherical base of standard MDI cans. MDI cans having an ellipsoidal base offer the further advantage of facilitating the coating process.

The drug metering valve consists of parts usually made of stainless steel, a pharmacologically inert and propellant resistant polymer, such as acetal, polyamide (e.g., Nylon[®]), polycarbonate, polyester, fluorocarbon polymer (e.g., Teflon[®]) or a combination of these materials. Additionally, seals and "O" rings of various materials (e.g., nitrile rubbers, polyurethane, acetyl resin, fluorocarbon polymers), or other elastomeric materials are employed in and around the valve.

Fluorocarbon polymers for use in the invention include fluorocarbon polymers which are made of multiples of one or more of the following monomeric units: tetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), perfluoroalkoxyalkane (PFA), ethylene tetrafluoroethylene (ETFE), vinylidenefluoride (PVDF), and chlorinated ethylene tetrafluoroethylene. Fluorinated polymers which have a relatively high ratio of fluorine to carbon, such as perfluorocarbon polymers e.g. PTFE, PFA, and FEP, are preferred.

The fluorinated polymer may be blended with non-fluorinated polymers such as polyamides, polyimides, polyethersulfones, polyphenylene sulfides and amine-formaldehyde thermosetting resins. These added polymers improve adhesion of the polymer coating to the can walls. Preferred polymer blends are PTFE/FEP/polyamideimide, PTFE/polyethersulphone (PES) and FEP-benzoguanamine.

Particularly preferred coatings are pure PFA, FEP and blends of PTFE and polyethersulphone (PES).

Fluorocarbon polymers are marketed under trademarks such as Teflon®, Tefzel®, Halar®, Hostaflon®, Polyflon® and Neoflon®. Grades of polymer include FEP DuPont 856-200, PFA DuPont 857-200, PTFE-PES DuPont 3200-100, PTFE-FEP-polyamideimide DuPont 856P23485, FEP powder DuPont 532 and PFA 5 Hoechst 6900n. The coating thickness is in the range of about 1µm to about 1mm. Suitably the coating thickness is in the range of about 1µm to about 100µm, e.g. 1µm to 25µm. Coatings may be applied in one or more coats.

10 Preferably the fluorocarbon polymers for use in the invention are coated onto MDI cans made of metal, especially MDI cans made of aluminium or an alloy thereof.

15 The particle size of the particular (e.g., micronised) drug should be such as to permit inhalation of substantially all the drug into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than microns, and, in particular, in the range of 1-10 microns, e.g., 1-5 microns.

20 The final aerosol formulation desirably contains 0.005-10% weight to weight ratio, in particular 0.005-5% weight to weight ratio, especially 0.01-1.0% weight to weight ratio, of drug relative to the total weight of the formulation.

25 A further aspect of the present invention is a metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more fluorocarbon polymers, for dispersing an inhalation drug formulation comprising beclomethasone dipropionate and a fluorocarbon propellant optionally in combination with one or more other pharmacologically active agents and one or more excipients.

A particular formulation for use in the metered dose inhaler of the present invention comprises:

- 30 (a) beclomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns;
- (b) at least 0.015% by weight of the formulation of water in addition to the water of crystallization associated with said monohydrate; and
- (c) a fluorocarbon propellant.

Such aerosol formulations desirably contain at least 0.015% (e.g., 0.015 to 0.1%) by weight of the formulation of water (excluding the water of crystallization associated with the beclomethasone dipropionate monohydrate), preferably at

5 least 0.02%, for example 0.025% by weight or more of added water. Preferred formulations according to the invention contain at least 0.026%, for example 0.026 to 0.08% by weight of water, in addition to the water of crystallization associated with the beclomethasone dipropionate monohydrate. Optionally, a cosolvent such as ethanol may be included in the formulation in the desired 10 amount. Suitably, the formulation may contain 0.05 to 3.0% w/w based on the propellant of a polar cosolvent such as ethanol. Preferably the fluorocarbon propellant is 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane.

15 Further drug formulations for use in the invention are free or substantially free of surfactants. Thus, a further formulation comprises or consists essentially of beclomethasone dipropionate or a physiologically acceptable solvate thereof, optionally in combination with one or more other pharmacologically active 20 agents, a fluorocarbon propellant and 0.01 to 0.05% w/w based on the propellant of a polar cosolvent such as ethanol, which formulation is free of surfactant. Preferably the propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane, although mixtures thereof may also be used.

25 A particular aspect of the present invention is an MDI having part or essentially all of its internal surfaces e.g. metallic surfaces coated with PFA or FEP, or blended fluoropolymer resin systems such as PTFE-PES with or without a proper coat of polyamideimide or polyethersulfone for dispersing a drug formulation as defined hereinabove. Preferably the MDI can is made of aluminum or an alloy thereof.

30 The MDI can may be coated by the means known in the art of metal coating. For example, a metal, such as aluminum or stainless steel, may be precoated as coil stock and cured before being stamped or drawn into the can shape. This method is well suited to high volume production for two reasons. First, the art of

coating coil stock is well developed and several manufacturers can custom coat metal coil stock to high standards of uniformity and in a wide range of thicknesses. Second, the precoated stock can be stamped or drawn at high speeds and precision by essentially the same methods used to draw or stamp

5 uncoated stock.

Other techniques for obtaining coated cans is by electrostatic dry powder coating or by spraying preformed MDI cans inside with formulations of the coating fluorinated polymer/polymer blend and then curing. The preformed MDI cans 10 may also be dipped in the fluorocarbon polymer/polymer blend coating formulation and cured, thus becoming coated on the inside and out. The fluorocarbon polymer/polymer blend formulation may also be poured inside the MDI cans then drained out leaving the insides with the polymer coat. Conveniently, for ease of manufacture, preformed MDI cans are spray-coated 15 with the fluorinated polymer/polymer blend.

The fluorocarbon polymer/polymer blend may also be formed in situ at the can walls using plasma polymerization of the fluorocarbon monomers. Fluorocarbon polymer film may be blown inside the MDI cans to form bags. A variety of 20 fluorocarbon polymers such as ETFE, FEP, and PTFE are available as film stock.

The appropriate curing temperature is dependent on the fluorocarbon polymer/polymer blend chosen for the coating and the coating method employed. However, for coil coating and spray coating temperatures in excess of the melting 25 point of the polymer are typically required, for example, about 50° C above the melting point for up to about 20 minutes such as about 5 to 10 minutes eg about 8 minutes or as required. For the above named preferred and particularly preferred fluorocarbon polymer/polymer blends curing temperatures in the range of about 300°C to about 400°C, e.g. about 350°C to 380°C are suitable. For 30 plasma polymerization typically temperatures in the range of about 20°C to about 100°C may be employed.

The fluorocarbon polymer may also be formed in situ at the can walls using plasma polymerization of the fluorocarbon monomers. Fluorocarbon polymer film

may be blown inside the MDI cans to form bags. A variety of fluorocarbon polymers such as ETFE, FEP, and PTFE are available as film stock.

The MDI's taught herein may be prepared by methods of the art (e.g., see Byron,
5 above and U.S. patent 5,345,980) substituting conventional cans for those
coated with a fluorinated polymer. That is, beclomethasone dipropionate and
other components of the formulation are filled into an aerosol can coated with a
fluorinated polymer. The can is fitted with a cap assembly which is crimped in
place. The suspension of the drug in the fluorocarbon propellant in liquid form
10 may be introduced through the metering valve as taught in U.S. 5,345,980
incorporated herein by reference.

The MDI's with fluorocarbon coated interiors taught herein may be used in
medical practice in a similar manner as non-coated MDI's now in clinical use.
15 However the MDI's taught herein are particularly useful for containing and
dispensing inhaled drug formulations with hydrofluoroalkane fluorocarbon
propellants such as 134a with little, or essentially no, excipient and which tend to
deposit or cling to the interior walls and parts of the MDI system. In certain case
it is advantageous to dispense an inhalation drug with essentially no excipient,
20 e.g., where the patient may be allergic to an excipient or the drug reacts with an
excipient.

MDI's containing the formulations described hereinabove, MDI systems and the
use of such MDI systems for the treatment of respiratory disorders e.g. asthma
25 comprise further aspects of the present invention.

It will be apparent to those skilled in the art that modifications to the invention
described herein can readily be made without departing from the spirit of the
invention. Protection is sought for all the subject matter described herein
30 including any such modifications.

The following non-limitative Examples serve to illustrate the invention.

EXAMPLES**Example 1**

5 Standard 12.5 mL MDI cans (Presspart Inc., Cary, NC) were spray-coated (Livingstone Coatings, Charlotte, NC) with primer (DuPont 851-204) and cured to the vendor's standard procedure, then further spray-coated with either FEP or PFA (DuPont 856-200 and 857-200, respectively) and cured according to the vendor's standard procedure. The thickness of the coating is approximately 10 μ m to 50 μ m. These cans are then purged of air (see PCT application number 10 W094/22722 (PCT/EP94/00921)), the valves crimped in place, and a suspension of about 24 mg beclomethasone dipropionate in about 18 gm P134a is filled through the valve.

Example 2

15 Standard 0.46 mm thick aluminum sheet (United Aluminum) was spray-coated (DuPont, Wilmington, DE) with FEP (DuPont 856-200) and cured. This sheet was then deep-drawn into cans (Presspart Inc., Cary, NC). The thickness of the coating is approximately 10 μ m to 50 μ m. These cans are then purged of air, the valves crimped in place, and a suspension of about 60 mg beclomethasone dipropionate in about 18 gm P134A is filled through the valve.

Example 3

25 Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped 30 in place, and a suspension of about 68mg micronised beclomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.

Example 4

5 Standard 12.5ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air the valves crimped in place, and a suspension of about 68mg micronised beclomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.

10

Example 5

15 Standard 12.5ml MDI cans (Presspart Inc., Cary NC) are spray-coated with FEP powder (DuPont FEP 532) using an electrostatic gun. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and a suspension of about 68mg micronised beclomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.

20

Example 6

25 Standard 0.46mm thick aluminium sheet is spray coated with FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and a suspension of about 68mg micronised beclomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.

30

Example 7

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with an aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans

are then purged of air, the valves crimped in place, and a suspension of about 68mg micronised beclomethasone dipropionate monohydrate in about 6.1mg water and about 18.2g P134a is filled through the valve.

5

Example 8

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and about 68mg micronised beclomethasone dipropionate monohydrate in about 182mg ethanol and about 18.2g P134a is filled through the valve.

15

Example 9

Standard 12.5ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air the valves crimped in place, and about 68mg micronised beclomethasone dipropionate monohydrate in about 182mg ethanol and about 18.2g P134a is filled through the valve.

25

Example 10

Standard 12.5ml MDI cans (Presspart Inc., Cary NC) are spray-coated with FEP powder (DuPont FEP 532) using an electrostatic gun. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and about 68mg micronised beclomethasone dipropionate monohydrate in about 182mg ethanol and about 18.2g P134a is filled through the valve.

Example 11

Standard 0.46mm thick aluminium sheet is spray coated with FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans. These
5 cans are then purged of air, the valves crimped in place, and about 68mg micronised beclomethasone dipropionate monohydrate in about 182mg ethanol and about 18.2g P134a is filled through the valve.

Example 12

10 Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with an aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and about 68mg micronised beclomethasone dipropionate monohydrate in about 182mg ethanol and about
15 18.2g P134a is filled through the valve.

Example 13

20 Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and about 13.6mg micronised beclomethasone dipropionate in about
25 107mg ethanol and about 21.4g P227 is filled through the valve.

Example 14

30 Standard 12.5ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air the valves crimped in place, and about 13.6mg micronised beclomethasone dipropionate in about 107mg ethanol and about 21.4g P227 is filled through the valve.

Example 15

5 Standard 12.5ml MDI cans (Presspart Inc., Cary NC) are spray-coated with FEP powder (DuPont FEP 532) using an electrostatic gun. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and about 13.6mg micronised beclomethasone dipropionate in about 107mg ethanol and about 21.4g P227 is filled through the valve.

10

Example 16

15 Standard 0.46mm thick aluminium sheet is spray coated with FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and about 13.6mg micronised beclomethasone dipropionate in about 107mg ethanol and about 21.4g P227 is filled through the valve.

20

25 Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with an aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the coating is between approximately 1 μ m and approximately 20 μ m. These cans are then purged of air, the valves crimped in place, and about 13.6mg micronised beclomethasone dipropionate in about 107mg ethanol and about 21.4g P227 is filled through the valve.

Examples 18-22

30 Examples 3 to 7 are repeated except that about 24mg salbutamol as the free base or equivalent weight of salt e.g. sulphate with about 12mg beclomethasone dipropionate monohydrate in about 364mg ethanol and about 18.2g P134a is filled through the valve.

Examples 23-42

Examples 3 to 22 are repeated except that modified 12.5ml MDI cans having a substantially ellipsoidal base (Presspart Inc., Cary NC) are used.

5

Dose delivery from the MDIs tested under simulated use conditions is found to be constant, compared to control MDIs filled into uncoated cans which exhibit a significant decrease in dose delivered through use.

We claim:

1. A metered dose Inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.
- 5 2. An inhaler according to Claim 1 containing said drug formulation.
- 10 3. An inhaler according to Claim 2 wherein said drug formulation further comprises a surfactant.
- 15 4. An inhaler according to Claim 2 or Claim 3 wherein said drug formulation further comprises a polar cosolvent.
- 20 5. An inhaler according to claim 2 wherein said drug formulation comprises 0.01 to 5 % w/w based on the weight of propellant of a polar cosolvent, which formulation is substantially free of surfactant.
- 25 6. An inhaler according to Claim 4 or Claim 5, wherein the polar cosolvent is ethanol.
- 30 7. An inhaler according to any one of Claims 2 to 6, wherein said drug formulation comprises beclomethasone dipropionate or a physiologically acceptable solvate thereof in combination with salmeterol or salbutamol or a physiologically acceptable salt thereof.
8. An inhaler according to Claim 2, wherein said drug formulation comprises
 - (a) beclomethasone dipropionate monohydrate, the particle size of substantially all the monohydrate being less than 20 microns;
 - (b) at least 0.15% by weight of the formulation of water in addition to the water of crystallisation associated with the monohydrate; and

(c) a fluorocarbon propellant.

9. An inhaler according to Claim 8, wherein the formulation further comprises 0.05 to 3% w/w based on the propellant of a polar cosolvent.

5

10. An inhaler according to Claim 9, wherein the polar cosolvent is ethanol.

11. An inhaler according to Claim 2, wherein said drug formulation consists essentially of beclomethasone dipropionate or a physiologically acceptable solvate thereof, optionally in combination with one or more other pharmacologically active agents, a fluorocarbon propellant and 0.01 to 5 % w/w based on the propellant of a polar cosolvent, which formulation is substantially free of surfactant.

15 12. An inhaler according to any one of Claims 2 to 11, wherein the fluorocarbon propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof.

20 13. An inhaler according to Claim 12, wherein the fluorocarbon propellant is 1,1,1,2-tetrafluoroethane.

14. An inhaler according to any one of claims 1 to 13 comprising a can made of metal wherein part or all of the internal metallic surfaces are coated.

25 15. An inhaler according to Claim 14 wherein the metal is aluminium or an alloy thereof.

16. An inhaler according to any one of Claims 1 to 15, wherein said fluorocarbon polymer is a perfluorocarbon polymer.

30 17. An inhaler according to Claim 16 wherein said fluorocarbon polymer is selected from PTFE, PFA, FEP and mixtures thereof.

18. An inhaler according to any one of Claims 1 to 17, wherein said fluorocarbon polymer is in combination with a non-fluorocarbon polymer selected from polyamideimide and polyethersulphone.

5 19. An inhaler according to any one of Claims 1 to 18 comprising a substantially ellipsoidal base.

10 20. A metered dose inhaler system comprising a metered dose inhaler according to any one of Claim 1 to 19 fitted into suitable channelling device for oral or nasal inhalation of the drug formulation.

21. Use of a metered dose inhaler system according to Claim 20 for the treatment of respiratory disorders.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/05009

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,93 11743 (GLAXO GROUP LTD) 24 June 1993 see page 4, line 18-21 see page 5, line 19-26 see page 7, line 27 - page 8, line 2 see page 8, line 21-28 see examples 12,14 see claims 19,20 ---	2,7
Y	WO,A,92 08446 (GLAXO GROUP LTD) 29 May 1992 see page 2, line 6-13 see page 3 - page 5, paragraph 1 see claims 1-3,5,7,10 ---	3,4,6,11
Y	WO,A,94 03153 (GLAXO GROUP LTD ;TAYLOR ANTHONY JAMES (GB); NEALE PHILIP JOHN (GB)) 17 February 1994 see page 4, line 18-22 see page 5, line 17-29 see page 7, line 26-29 see page 8, line 14-20 see claim 11 ----	5,8-10
A	WO,A,81 01375 (GLYCO METALL WERKE ;STERNISA D (DE); SCHNEIDER W (DE); HODES E (DE) 28 May 1981 see page 3, line 20-26 see page 4, line 11-18 see page 5, line 12-17 -----	18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/05009

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-642992	15-03-95	AU-B-	7142994	09-03-95
		CA-A-	2130867	28-02-95
		JP-A-	7076380	20-03-95
US-A-5176132	05-01-93	US-A-	5482946	09-01-96
		US-A-	5341800	30-08-94
		AT-T-	111364	15-09-94
		CA-A-	2017883	30-11-90
		DE-D-	69012458	20-10-94
		DE-T-	69012458	09-03-95
		DE-T-	407028	17-03-94
		EP-A-	0407028	09-01-91
		ES-T-	2060040	16-11-94
		JP-A-	3018376	25-01-91
US-A-5202110	13-04-93	NONE		
WO-A-9311743	24-06-93	AP-A-	402	22-08-95
		AU-B-	663904	26-10-95
		AU-B-	3085092	19-07-93
		BG-A-	98803	28-02-95
		CA-A-	2125667	24-06-93
		CZ-A-	9401430	15-03-95
		EP-A-	0616523	28-09-94
		HU-A-	67534	28-04-95
		JP-T-	7502033	02-03-95
		NO-A-	942185	10-06-94
		NZ-A-	246044	26-01-96
		OA-A-	9926	15-09-94
		SK-A-	67494	08-03-95
		ZA-A-	9209617	22-03-94
		AU-B-	663905	26-10-95
		AU-B-	3085192	19-07-93
		CA-A-	2125666	24-06-93
		WO-A-	9311744	24-06-93
		EP-A-	0616524	28-09-94
		JP-T-	7502034	02-03-95
		AT-T-	128350	15-10-95
		AU-B-	663906	26-10-95
		AU-B-	3085292	19-07-93

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/05009

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 21 because they relate to subject matter not required to be searched by this Authority, namely:
Method of treatment of the human or animal body by therapy.
See Rule 39.1(iv) PCT.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/05009

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9311743		CA-A- 2125665 CN-A- 1075078 CN-A- 1075079 DE-D- 69205177 DE-T- 69205177 WO-A- 9311745 EP-A- 0616525 ES-T- 2079210 JP-T- 7501811 NZ-A- 246046	24-06-93 11-08-93 11-08-93 02-11-95 21-03-96 24-06-93 28-09-94 01-01-96 23-02-95 21-12-95
WO-A-9208446	29-05-92	AT-T- 127013 AU-B- 660952 AU-B- 8877891 CA-A- 2094726 DE-D- 69112637 DE-T- 69112637 EP-A- 0556256 ES-T- 2078551 JP-T- 6501700	15-09-95 13-07-95 11-06-92 10-05-92 05-10-95 08-02-96 25-08-93 16-12-95 24-02-94
WO-A-9403153	17-02-94	AU-B- 4705093 CA-A- 2141039 CN-A- 1088436 EP-A- 0658101 JP-T- 7509475 ZA-A- 9305477	03-03-94 17-02-94 29-06-94 21-06-95 19-10-95 23-02-94
WO-A-8101375	28-05-81	DE-A- 2947025 DE-C- 3050056 GB-A,B 2075368	04-06-81 16-06-88 18-11-81